Verve Therapeutics Shares Gain 16% On 4Q Revenue Beat

By Ben Glickman Shares of Verve Therapeutics rose Tuesday after fourth-quarter collaboration revenue came in ahead of expectations. The stock was up 16% to...

Related Keywords

Boston ,Massachusetts ,United States ,Sekar Kathiresan ,Ben Glickman ,Eli Lilly ,Vertex Pharmaceuticals ,Verve Therapeutics ,Executive Sekar Kathiresan ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Scientific Research Services ,Healthcare Life Sciences ,Business Consumer Services ,Biopharmaceuticals ,Biological Therapy ,Medical Research Services ,Drug Discovery Development ,Healthcare Provision ,Healthcare Support Services ,Diagnostic Medical Research Services ,Financial Performance ,Earnings ,Sales Figures ,Share Price Movement Disruptions ,Corporate Industrial News ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Synd ,Vrtx ,Everv ,Share Price Movement ,Disruptions ,Corporate ,Industrial News ,Healthcare ,Life Sciences ,Business ,Consumer Services ,Drug Discovery ,Development ,Diagnostic ,